ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO1198

CD11b Deficiency Ameliorates AKI-to-CKD Progress via Promoting Alternative Activation of Macrophages

Session Information

  • CKD: Mechanisms - 3
    October 26, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms

Author

  • Shi, Yiqin, Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China
Background

Acute kidney injury (AKI), even if followed by renal recovery, is a risk factor for the future development of chronic kidney disease (CKD). Persistent chronic inflammation has been proposed to contribute to the progress of AKI-to-CKD. Macrophages are a heterogeneous cell group implicated in injury, repair, and fibrosis during AKI-to-CKD process. However, the underlying mechanism of how macrophages participate in the progress of disease is largely unclear. CD11b/CD18, a leukocyte adhesion molecule, expressed on neutrophils, eosinophils and macrophages, has been shown to mediate several adhesion-dependent processes. CD11b/CD18 also contributes to the polarization of macrophages.

Methods

To determine the underlying mechanism of how CD11b/CD18 participates in AKI-to-CKD, we use a long-term ischemia/reperfusion (I/R) model in CD11b-/- mice on C57BL/6 background. Wild-type (WT) and CD11b-/- mice with unilateral renal IRI were euthanized at day 3,7,14 after disease induction. Organ damage was histologically analyzed and flow cytometric analysis, real-time PCR were performed for the evaluation of leukocyte infiltration in kidney. In vitro, we used murine bone marrow-derived macrophage (BMDM) from WT and CD11b -/- mice to determine IL-4 induced alternatively activated (M2) macrophage associated gene expression.

Results

The extent of inflammation and fibrosis was alleviated in CD11b-/- mice, accompanied by an early increase of M2 macrophages in renal and higher activity of p-STAT6. We demonstrated both in vitro and in vivo that enhanced alternative activation in CD11b-knockout macrophages is regulated by the IL-4/STAT6 axis, which is mediated by the inactivation of the Src kinase family member Lyn. Importantly, the therapeutical administration of CD11b-neutralizing mAbs can effectively prevent AKI-to-CKD progression.

Conclusion

CD11b plays a critical role in limiting the alternative activation of macrophages and may be a potential therapeutic target during the AKI-to-CKD process.